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ABSTRACT  
Objective: The aim of the present study was to evaluate the effect of prophylactic inhibition of inducible nitric oxide synthase (iNOS) by 
aminoguanidine (AG) on serum levels of some adipocytokines in pristane-induced arthritis in rats. 
Methods: Forty white Albino rats were divided randomly into four groups; each group was composed of ten rats (five male and five female). Group I 
(AP) has received AG (100 mg/kg/day) i. p. for seven days, and then at day 8, has received single 150 µl pristane dose sc. at the base of rat’s tail. 
Group II (PC) has only received single 150 µl pristane sc. at the base of rat’s tail, at day 8 from the start of the experiment. Group III (AC) has only 
received AG (100 mg/kg/day)i. p. for seven days. Group VI (VC) has only received normal saline via i. p. injection for seven days. At the end of the 
experiment time, rats were sacrificed, and serum samples were obtained and used for the measurement of iNOS, rheumatoid factor (RF), c-reactive 
protein (CRP), tumor necrosis factor-alpha (TNF-α), interleukine-6 (IL-6), leptin and adiponectin levels, using the corresponding rat ELISA kits.  
Results: Administration of pristane for the induction of RA has resulted in significant increase in all of the measured parameters in PC group as 
compared to VC and AC groups, except for iNOS where the increase was significant as compared to AC group only. Serum levels of RF, CRP and IL-6 in AP 
group have showed to be significantly elevated as compared to VC and AC groups. Administration of AG has resulted in different levels of reduction in all 
of the measured parameters in AP group as compared to PC group. The reduction was statistically significant with regard to CRP and leptin. 
Conclusion: prophylactic administration of the selective iNOS inhibitor AG, has resulted in a reduction in serum levels of the measured 
adipocytokines which may reflect a reduction in the severity of PIA. 
Keywords: Adipocytokines, Aminoguanidine, iNOS, Pristane, Rheumatoid Arthritis. 
 
INTRODUCTION 
Rheumatoid arthritis (RA) is a chronic, progressive, polyarthritic 
autoimmune disease associated with articular, and extra-articular or 
systemic effects [1]. It is one of the most common arthritides in 
western populations, with an estimated prevalence of 0.5-1.0% 
among adults. RA is more prevalent among women than men with a 
female preponderance of 2-3:1 [2, 3]. 
The perception of adipose tissue, as an organ that merely passively 
store excess fat and act as an energy store has changed. It is now 
considered as an endocrine organ that has an important role in 
regulating diverse physiological functions. This regulation is mediated 
by the action of biological mediators called “adipocytokines”. 
More than 50 different adipocytokines are currently recognized to be 
secreted from adipose tissue. These adipocytokines are implicated in the 
modulation of a range of physiological functions such as inflammation, 
glucose homeostasis, lipid metabolism, blood coagulation, angiogenesis, 
and blood pressure [4]. Adipose tissue produces and releases a variety of 
proinflammatory and anti-inflammatory factors, including the 
adipokines leptin, adiponectin, resistin, and visfatin, cytokines such as 
TNF-α, IL-6, and many others [5]. 
Nitric oxide (NO) is a free-radical messenger molecule that is 
produced from the amino acid L-arginine by the enzymatic action of 
NO synthase (NOS) [6]. Nitric oxide synthase (NOS) is available in 
both constitutive and inducible forms. Three different nitric oxide 
synthase (NOS) proteins have been identified, eNOS, iNOS and nNOS 
(endothelial, inducible and neuronal NOS, respectively) [7]. 
In autoimmune reactions and other forms of chronic inflammation, 
NO and NO-derived radicals can harm the host tissues [8]. Among its 
various biological actions, NO inhibits chondrocytes synthesis of 
collagen and proteoglycan, stimulates matrix metalloproteinases, 
and promotes vasodilation, which facilitates the influx of fluid and 
cells in to an inflammatory site. Furthermore, NO combines with 
reactive oxygen species, forming peroxynitrite, which promotes 
chondrocyte apoptosis [9]. 
Elevated NO production has been reported in RA patients [10, 
11], and the increased urinary nitrite (metabolite of NO) 
concentrations have been shown to diminish after prednisolone 
treatment [12]. Elevated levels of NO were shown to correlate 
with several RA disease activity parameters [13]. Increased iNOS 
expression and NO production have also been detected in animal 
models of arthritis [14, 15], and the use of NOS inhibitors have 
been shown to have beneficial effects in experimentally induced 
arthritis [16, 17]. 
Aminoguanidine (AG) is a selective inhibitor of iNOS. It is over 50-
fold more effective at inhibiting the enzymatic activity of iNOS than 
endothelial or neuronal isoforms of NOS [18].  
Pristane-induced arthritis (PIA) in rats resembles the human disease 
such as in the development of symmetrical disease, the presence of 
serum rheumatoid factors, radiographic changes and chronicity [19]. 
The aim of the present study was to evaluate the effect of 
prophylactic iNOS inhibition by AG on serum levels of some 
adipocytokines in PIA in rats. 
MATERIALS AND METHODS 
Experimental animals 
Forty white Albino rats of comparable age and sex, and weighing 
150-200 gm were used in this study; they were obtained from and 
maintained in the Animal House of the Pharmacy College, University 
of Baghdad, in a climate-controlled environment. The animals were 
housed in polystyrene cages containing wood shavings and fed 
standard rodent chow and water ad libitum. The study was 
approved by the ethical committee at the Pharmacy College, 
University of Baghdad (Ethical approval number 5537; date 30th 
November 2014). 
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PIA induction and evaluation of arthritis 
PIA was induced by a single subcutaneous (s. c.) injection of 150μl 
pristane (2,6,10,14-tetramethylpentadecane; Sigma-Aldrich, St. 
Louis, Missouri, USA) at the base of rat’s tail[19] at the age of 8–12 
w. Arthritis development and severity were monitored in all four 
limbs every seven days by the perimeters of ankle and mid-paw, and 
a macroscopic scoring system. Briefly, the development of arthritis 
was monitored using a macroscopic scoring system for the four 
limbs ranging from 0-4 (1 = swelling and redness of one joint, 2 = 
two joints involved, 3 = more than two joints involved, and 4 = 
severe arthritis in the entire paw). The scores of the four paws were 
added, yielding a maximum total score of 16 for each rat [20]. 
Preparation of AG solution for injection 
The daily dose of AG (Aminoguanidine HCl; Sigma-Aldrich, St. Louis, 
Missouri, USA) was prepared by dissolving the required amount in 
normal saline, and the dose was administered intraperitoneally (i. 
p.). AG dosage (100 mg/kg) was selected depending on the levels 
used effectively in experimental animal models for iNOS blockage 
[21-23]. 
Experimental protocol 
Forty white Albino rats were enrolled in this experiment. The rats 
were divided randomly into four groups; each group was composed 
of ten rats, five of which were male and five were female. The study 
groups was treated as follows:  
Group I (AP): has received AG treatment (100 mg/kg/day) i. p. for 
seven days, and then at day 8, has received single 150 µl pristane 
dose sc. at the base of rat’s tail for the induction of RA. 
Group II (PC): has received the pristane dose only (single 150 µl 
pristane sc. at the base of rat’s tail for the induction of RA), at day 8 
from the start of the experiment. 
Group III (AC): has only received the AG treatment (100 
mg/kg/day) i. p. for seven days. 
Group VI (VC): has only received the solvent (normal saline) via i. p. 
injection for seven days. 
Preparation of serum samples  
After four weeks of last treatment, the animals have been 
anesthetized by ether, and then the blood was collected by cervical 
decapitation and transferred into a plain tube and left to clot for ten 
minutes before being centrifuged at 2,000 rpm for another 10 min. 
The sera were collected using rubber micropipette and divided into 
small aliquots in Eppendorf tubes and kept frozen till the time of 
analysis. 
Biochemical analysis 
Serum levels of iNOS, rheumatoid factor (RF), c-reactive protein 
(CRP), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), 
leptin, and adiponectin were measured by quantitative enzyme-
linked immunosorbent assay (ELISA), using the corresponding 
readymade kits purchased from (Elabscience Biotechnology; China), 
and according to the manufacturer instructions. 
Statistical analysis 
Analysis of data was performed using GraphPad Prism software 
version 6.05 for Windows (GraphPad, San Diego, CA, USA). Values 
are presented as mean±SEM. The significance of difference among 
groups was tested by one-way analysis of variance (ANOVA), 
followed by Tukey’s post hoc analysis to compensate for multiple 
testing. Homogeneity of variance was tested by, Brown-Forsythe’s 
and Bartlett's Test. Statistical significance was considered whenever 
the P value was equal or less than 0.05. 
RESULTS  
Administration of pristane for the induction of RA has resulted in 
significant increase in all of the measured parameters in PC group as 
compared to VC and AC groups, except for iNOS where the increase 
was significant as compared to AC group only [(9.760±1.091 ng/ml vs. 
5.100±0.6495 ng/ml for iNOS), (8.828±0.686kIU/lvs. 1.503±0.3833 
kIU/land 1.786±0.3642kIU/l for RF), (22.15±1.532 mg/l vs. 
7.06±0.760 mg/l and 9.01±1.238 mg/l for CRP), (55.00±4.874 pg/ml 
vs. 25.98±4.667 pg/ml and 34.79±5.346 pg/ml for TNF-α), 
(704.3±52.01 pg/ml vs. 175.5±30.71 pg/ml and 170.6±28.43 pg/ml 
for IL-6), (3.422±0.1923µg/l vs. 1.623±0.1857µg/land 1.998± 
0.2108µg/l for leptin) and (47.09±3.464 ng/ml vs. 32.71±4.003 ng/ml 
and 33.26±3.822 ng/ml for adiponectin) respectively]. In AG 
treatment group (AP group), serum levels of RF, CRP and IL-6 have 
showed to be significantly elevated as compared to VC and AC groups 
[(7.913±0.4628kIU/l vs. 1.503±0.3833kIU/land 1.786±0.3642kIU/l 
for RF), (15.88 mg/l±1.416 vs. 7.06±0.760 mg/l and 9.01±1.238 mg/l 
for CRP) and (676.0±58.15 pg/ml vs. 175.5±30.71 pg/ml and 
170.6±28.43 pg/ml for IL-6) respectively], as shown in table1. 
Administration of AG has resulted in different levels of reduction in 
all of the measured parameters in AP group as compared to PC 
group. The reduction was statistically significant with regard to CRP 
and leptin [(15.88±1.416 mg/l vs. 22.15±1532 mg/l for CRP) and 
(1.917±0.2208µg/l vs. 3.422±0.1923µg/l for leptin) respectively], as 
shown in table 1. 
 
Table 1: Serum levels of the studied parameters 
 VC n=10 AC n=10 PC n=10 AP n=10 ANOVA P-value 
iNOS (ng/ml) 6.211±1.239 5.100±0.6495 9.760±1.091 7.200±0.8868 b 0.0152 
RF (kIU/l) 1.503±0.3833 1.786±0.3642 8.828±0.686 7.913±0.4628a,b <0.0001 a,b 
CRP (mg/l) 7.06±0.760 9.01±1.238 22.15±1.532 15.88±1.416a,b,c <0.0001 a,b 
TNF-α (pg/ml) 25.98±4.667 34.78±5.346 55.00±4.874 40.11±3.402 a,b <0.0009 
IL-6 (pg/ml) 175.5±30.71 170.6±28.43 704.3±52.01 676.0±58.15a,b <0.0001 a,b 
Leptin (µg/l) 1.623±0.1857 1.998±0.2108 3.422±0.1923 1.917±0.2208 a,b,c <0.0001 
Adiponectin (ng/ml) 32.71±4.003 33.26±3.822 47.09±3.464 44.27±2.356 a,b 0.0082 
Data are expressed as mean±SEM, VC= Vehicle control group, AC= Aminoguanidine control group, PC= Pristanecontrol group, AP= Treatment group 
(Aminoguanidine+Pristane), iNOS: Inducible Nitric Oxide Synthase, RF: Rheumatoid Factor, CRP: C - reactive protein, TNF-α: Tumor Necrosis 
Factor-alpha, IL-6: Interleukon-6. a = Significant difference as compared to VC group, b=Significant difference as compared to AC group, c
 
= Significant 
difference as compared to AP group. A significant difference between groups is considered using ANOVA test whenever (P<0.05). 
DISCUSSION  
The detailed mechanisms of RA pathogenesis are not totally 
understood, and hence, the factors responsible for the initiation and 
progression of this disease are the core subject of many studies. The 
articular and synovial adipose tissue represents an important entity 
of human joints, and local and systemic alteration in the synthesis, 
release, and receptor action of adipocytokines needs further study to 
elucidate the potential role of these adipocytokines in RA. 
In the present study, the administration of pristane for the induction 
of AR has resulted in a significant elevation in serum levels of iNOS, 
RF, CRP, TNF-α, IL-6, leptin and adiponectin, in PC group as 
compared to VC group (table1). 
In addition to macrophages where it is primarily identified, iNOS 
expression can be induced almost in any cell or tissue, as long as the 
appropriate agents have induced its synthesis [24]. At the synovium 
of the inflamed joint macrophages, chondrocytes, osteoclasts and 
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osteoblasts express iNOS [25]. In addition, the inflamed synovium is 
invaded by T lymphocytes, B lymphocytes, neutrophils, monocytes, 
and dendritic cells [26] which also participate in iNOS expression. 
In the present study, the administration of AG a selective iNOS 
inhibitor has resulted in small, non-significant decrease in iNOS 
levels in AC group as compared to VC group. This is very expected 
since the enzyme is usually not expressed in the normal 
physiological conditions. Nevertheless, AG treatment has resulted in 
a profound reduction (still statistically non-significant), in iNOS 
levels in AP group as compared to PC group. iNOS expression (and 
action) is controlled by large and different regulatory 
mechanisms[27, 28]. Some of these regulators are bone derived [29, 
30]. On the other hand, adipose tissue has a role in inflammatory 
pathways, through the secretion of many cytokines that alter the 
expression of iNOS [31-34]. TNF-α has been found to upregulate 
iNOS transcription in synovial fibroblasts, articular chondrocytes 
and osteoblasts cultured from RA patients [10]. IL-6 also has been 
found to increase iNOS
Rheumatoid factors (RFs) are typically produced during secondary 
immune responses against infections or immunizations [40]. RFs are 
detected in 60–80% of RA patients [41]. High titer RF is associated 
with radiologic erosion, extra-articular manifestations and thus, 
poorer outcomes [41-44]. RF has proven to be the most useful 
disease marker of RA, as included in the American College of 
Rheumatology classification criteria for RA [45].  
 expression [35]. In human and murine 
chondrocytes, leptin synergizes with IL-1𝛽𝛽 and IFN𝛾𝛾 for the 
activation of iNOS [36-38]. In cultured chondrocytes, adiponectin 
increases the secretion and activity of many proinflammatory 
mediators, including iNOS [39]. Thus, elevated serum levels of TNF-
α, IL-6, leptin and adiponectin, reported in the present study may 
explain, at least in part, why AG has failed to bring down serum iNOS 
levels in the treatment group AP to that of VC group.  
The animal model that has been used in the present study, PIA rat model, 
resembles the human disease in the development of symmetrical 
disease, chronicity, radiographic changes and presence of serum RF [19].  
C-reactive protein (CRP) is an acute-phase reactant that is 
commonly used in the diagnosis and follow-up of disease activity in 
rheumatology clinics. Even though it is called acute phase reactants, 
CRP rises in both acute and chronic inflammatory conditions [46]. 
In the present study, the administration of pristane has resulted in 
significant increase in CRP levels in both PC and AP groups as 
compared to VC and AC groups. This is greatly expected since 
pristane induces both cellular and humoral responses during the 
course of RA induction [47]. 
The synthesis of CRP is regulated primarily by interleukin-6 (IL-6), 
which in turn is controlled by other inflammatory cytokines, for 
instance, TNF-α and IL-1[48-50]. This occurs in accordance with the 
results of the present study regarding IL-6 and TNF-α (table1), 
which has showed a significant increase in IL-6 and TNF-α in 
pristane-treated groups.  
Adipokines have been noted as new mediators of inflammatory 
processes [51, 52]. Many studies have demonstrated an elevated 
serum level of many adipokines in patients with RA, and an 
association between the levels of these adipokines and CRP [53-55]. 
In the present study serum levels of both leptin and adiponectin 
(table 1) have been shown to be elevated in pristane-treated groups. 
Thus, may further contribute to the elevated CRP levels. 
Tumor necrosis factor-alpha (TNF-α), exhibits both the 
proinflammatory and immunoregulatory properties of cytokines. It 
is produced mainly by monocytes and macrophages, but also by B-
cells, T-cells fibroblasts and adipocytes [56]. 
In the present study, the administration of pristane has resulted in 
significant increase in serum TNF-α level in PC group, as compared 
to VC and AC groups (table1). This result agrees with the findings of 
many clinical and experimental studies which have reported high 
synovial and serum levels of TNF-α in RA, and that TNF-α plays an 
important role in inflammation and joint destruction that are 
hallmarks of the disease [57-61]. 
TNF-α is one of the key cytokine molecules that causes inflammation 
in RA, by both direct [58], and indirect action through stimulating 
the release of other proinflammatory cytokines such as IL-6 [62-64]. 
Furthermore, TNF-α and leptin control the expression of each other. 
In one hand, TNF-α enhances the expression of leptin and its 
receptors [65]. On the other hand, leptin enhances TNF-α expression 
[66-68]. Thus, TNF-α may be an important contributor to the 
elevated serum levels of IL-6 and leptin, reported in the present 
study. 
Interlekin-6 (IL-6) plays a role in adaptive immune responses involved 
in the pathogenesis of RA. In addition, this cytokine is responsible for 
mediating many of the systemic manifestations of RA [50]. 
In the present study, the administration of pristane has resulted in 
significant increase in serum IL-6 levels in PC and AP groups as 
compared to VC and AC groups (table1). This result agrees with the 
clinical findings that have reported an excess production of IL-6 in 
the synovial fluid and blood of RA patients and correlates with the 
disease activity and joint destruction [69, 70].  
IL-6 induces the acute-phase response, particularly the development 
of CRP [71], which suggests that IL-6 contributes to the elevated 
serum levels of CRP reported in the present study. 
Leptin is mainly produced by white adipose tissue and the circulating 
levels of leptin correlate positively with the amount of adipose tissue 
and body mass index (BMI) [72]. However, leptin synthesis is also 
regulated by the action of inflammatory mediators [73]. 
In the present study, the administration of pristane has resulted in 
significant increase in leptin levels in PC group as compared to VC 
and AC group (table 1). This result is in accordance with many 
studies that have reported elevated leptin levels in patients with RA 
and that serum leptin correlates with synovial fluid: serum leptin 
ratio and disease duration and parameters of RA activity [74-76]. 
Moreover, leptin has been found to correlate with CRP level in RA 
patients, which indicates that it may act as a proinflammatory 
cytokine in RA [53]. Generally, leptin behaves as proinflammatory 
cytokine due to its synergistic role with IFN-γ and IL-1β on iNOS 
[36-38].  
The actions of leptin in RA are not only targeted to articular tissues, 
this adipokine also exerts direct modulatory effects on activation, 
proliferation, maturation and production of inflammatory mediators 
in a variety of immune cells, it activates monocyte/macrophage cells 
and increases production of the pro-inflammatory cytokines (TNF-α 
and IL-6) and reactive oxygen species (ROS) [77]. 
Some studies have reported conflicting data on serum levels of 
leptin in RA patients. Leptin levels were reported in some studies to 
be similar [78, 79], or even lower [80] in RA patients as compared 
with healthy controls. The discrepancies in the measured leptin 
levels may be attributed to the fact that, leptin levels are influenced 
by many factors such as body fat content, BMI, treatment, and 
disease activity and progression [81].  
Adiponectin is produced mainly by white adipose tissue. It has 
structural homology with collagens VIII and X and complements 
factor C1q and the proinflammatory cytokine TNF-α, and it 
circulates in the blood in relatively large amounts in different 
molecular forms [82, 83]. 
Adiponectin concentration is decreased in diseases associated with 
low-grade inflammation [84, 85]. Moreover, its production is 
suppressed by inflammatory cytokines such as TNF-α and IL-6 [34]. 
On the other hand, adiponectin exerts a variety of anti-inflammatory 
effects on metabolic pathways and vasculature [86]. However, 
adipokines are elevated in RA and other classical inflammatory 
diseases [87-89]. 
Despite the discrepancy, adiponectin may have proinflammatory 
rather than anti-inflammatory properties in RA. Adiponectin shares 
extensive sequence homologies with the complement factor C1q and 
the pro-inflammatory cytokine TNF-α [82, 83]. Furthermore, 
adiponectin has demonstrated to induce the production of IL-6 and 
pro-MMP1 [89-91], key mediators of destructive arthritis. 
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In the present study, the administration of pristane has resulted in 
significant increase in serum adiponectin levels in PC group as 
compared to VC and AC groups (table1). This result is in total 
agreement with the findings of many studies that have reported that 
the amount of adiponectin is increased in the synovial fluid [92], and 
serum[93]of patients with RA, with higher levels in erosive versus 
mild RA [93-95], and in chronic versus early RA [96].  
Articular adipose tissues may be the main source of adiponectin in 
RA, yet, serum adiponectin level has been reported to be higher than 
in synovial fluid in RA[93], suggesting that other systemic sources 
are more prominent than articular adipose tissues. Furthermore, the 
negative association of glomerular filtration rate and serum 
adiponectin level has been reported [97], indicating that impaired 
renal clearance of adiponectin may lead to increased adiponectin 
level in inflammatory diseases as well.  
Finally, in the present study the administration of the selective iNOS 
inhibitor AG, has resulted in a reduction in serum levels of RF, CRP, 
TNF-α, IL-6, leptin and adiponectin, in AP group as compared to PC 
group. The reduction was statistically significant with regard of CRP 
and leptin (table 1). This reduction may be attributed to the 
decrease in the severity of PIA by the administration of AG. 
This study is rather limited in terms of statistical power because of 
the small sample size and further large-scale animal and clinical 
studies are needed to establish our findings. Also, further work is 
required to confirm whether the reported effects are confined to AG 
or the whole members of iNOS inhibitors family of agents. 
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